Armstrong submits neurosurgical robot to the FDA
This article was originally published in Clinica
Neurosurgical robot maker Armstrong Healthcare has submitted to the FDA a 510(k) application for clearance to sell its PathFinder system in the US. The image-guided device, which is already CE-marked for sale in Europe, can allow surgeons to perform intracranial surgery more accurately, while reducing the duration and complexity of procedures. As well as its uses in procedures ranging from routine brain tumour biopsies to complex functional neurosurgery, the system may also have application in ground-breaking techniques such as gene therapy, claims the UK firm.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.